Who owns Fulcrum Therapeutics? - WallStreetZen

Who owns Fulcrum Therapeutics? Fulcrum Therapeutics ( NASDAQ : FULC ) is owned by 101.54% institutional shareholders, 61.37% Fulcrum Therapeutics insiders, and 0.00% retail …

54%
OFF

Who Owns Fulcrum Therapeutics? - WallStreetZen

1 week from now

Who owns Fulcrum Therapeutics? Fulcrum Therapeutics ( NASDAQ : FULC ) is owned by 101.54% institutional shareholders, 61.37% Fulcrum Therapeutics insiders, and 0.00% retail …

wallstreetzen.com

$13.50
OFF

Fulcrum Therapeutics Inc Stock - WallStreetZen

1 week from now

Dec 27, 2024 · Fulcrum Therapeutics. stock was originally listed at a price of $13.50 in Jul 18, 2019. If you had invested in Fulcrum Therapeutics stock at $13.50, your return over the last 5 …

wallstreetzen.com

89%
OFF

Fulcrum Therapeutics | FULC Stock Price, Company Overview

1 week from now

Fulcrum Therapeutics. FULC. Cambridge, Massachusetts. $4.15-0.08 (-1.89%) Share Price. as of December 19 11:51:49 AM EST. Upgrade to gain access to exclusive features and add your …

forbes.com

54%
OFF

FULC.A - | Stock Price & Latest News | Reuters

1 week from now

6 days ago · Fulcrum Therapeutics Inc FULC.A. Official Data Partner. Latest Trade. trading lower 4.26 USD. Change-0.25 % Change-5.54% Negative As of Jan 12, 2025. Values delayed up to …

reuters.com

77%
OFF

Fulcrum Therapeutics Revenue - WallStreetZen

1 week from now

Fulcrum Therapeutics 's revenue for the twelve months ending Dec 31, 2023 was $2.81 million, a 55.77% decrease year over year.Fulcrum Therapeutics 's annual revenue for Dec 31, 2022 …

wallstreetzen.com

09%
OFF

Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today

1 week from now

Aug 10, 2021 · What happened. Shares of Fulcrum Therapeutics (FULC-1.09%), an early clinical-stage biopharmaceutical company, are rocketing higher after an encouraging clinical trial …

fool.com

$17
OFF

Fulcrum Therapeutics Inc Earnings Dates, Reports, Calls

1 week from now

Fulcrum Therapeutics earnings were -$17.9M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest FULC earnings report on Sep 30, 2024 announced Q3 …

wallstreetzen.com

42%
OFF

Who Owns Iterum Therapeutics? - WallStreetZen

1 week from now

Who owns Iterum Therapeutics? Iterum Therapeutics ( NASDAQ : ITRM ) is owned by 7.42% institutional shareholders, 82.82% Iterum Therapeutics insiders, and 9.76% retail investors. Ra …

wallstreetzen.com

FAQs about Who owns Fulcrum Therapeutics? - WallStreetZen Coupon?

How much do Fulcrum Therapeutics insiders own?

A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Fulcrum Therapeutics insiders own 1.6% of the company, worth about US$9.9m. Whilst better than nothing, we're not overly impressed by these holdings. So What Does This Data Suggest About Fulcrum Therapeutics Insiders? ...

Who bought Fulcrum Therapeutics?

See our latest analysis for Fulcrum Therapeutics The CEO, President & Director Alexander Sapir made the biggest insider purchase in the last 12 months. That single transaction was for US$492k worth of shares at a price of US$11.35 each. ...

Are Fulcrum Therapeutics insiders doubting the company?

However, we don't see anything to make us think Fulcrum Therapeutics insiders are doubting the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Fulcrum Therapeutics. ...

Is Fulcrum Therapeutics a good stock to buy?

Fulcrum Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. ...

What pushed Fulcrum Therapeutics stock 76% higher on Monday?

Investors excited about the company's sickle-cell disease candidate pushed the stock 76% higher as of 10:35 a.m. EDT on Monday. This morning Fulcrum Therapeutics shared data from the company's first clinical trial. ...

Who is Fulcrum Therapeutics?

As of Dec 27, 2024. Values delayed up to 15 minutes Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. ...